ClinicalTrials.gg
Not yet recruitingNCT07377474Updated Jan 30, 2026

A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic Astigmatism

An interventional study of TENEO 317 Model 2 (1.28 US) Excimer Laser in Myopic Astigmatism, sponsored by Bausch & Lomb Incorporated. Not yet recruiting. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 23 studies in Astigmatism by Bausch Health Companies Inc. — 1 open to participants now, 1 under way, none of them phase 3. Astigmatism · Bausch Health Companies Inc..

Planned enrollment
14th of 19
32 · median 60
Started
2026
with 1 other
No phase
16 of 23
1 open now
Registered
23rd of 23
by date

Among the 23 studies in Astigmatism by Bausch Health Companies Inc., this one is the 14th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2026, is one of 16 with no phase, and was the 23rd registered.

Astigmatism

418 studies on the registry are indexed under Astigmatism; 51 are open to participants now.

Browse Astigmatism studies →

Open to participants now

1 of the 23 studies in Astigmatism by Bausch Health Companies Inc. is open now.

Who these studies take

Of the 32 Astigmatism studies recruiting now, 12 (38%) set no upper age limit and 15 (47%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Astigmatism by Bausch Health Companies Inc., or all of them as a file.
02

Study summary

This will be a multicenter, prospective, open label, non-randomized, single arm study evaluating the safety and effectiveness of the Technolas® TENEO 317 Model 2 (version 1.28 US software) Excimer Laser when used in LASIK surgery to treat myopia or myopic astigmatism. One or both eyes of a subject may be treated so long as both eyes meet all inclusion/exclusion requirements.

03

Conditions studied

  • Myopic Astigmatism

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are 22 years of age or older.
  2. Have read, understood, and signed an ICF.
  3. Have demonstrated stable refraction (i.e., a change of ≤ ± 0.5 D in sphere and cylinder) for a minimum of 12 months prior to surgery verified by consecutive refractions, medical records or prescription history.
  4. Have myopic refractive error with or without astigmatism; sphere 0.00 D up to -1.00 D, cylinder between 0.00 D and -3.00 D; with a manifest refraction spherical equivalent (MRSE) between -.0375 D and -2.50 D.
  5. Wears distance correction or has a need for distance correction.
  6. Have manifest, distance best spectacle corrected visual acuity (BSCVA) of 20/25 (logMAR 0.1) or better in an operative eye.
  7. Have equal to or less than 0.50 D spherical equivalent (SE) difference between cycloplegic and manifest refractions at Visit 1 (Pre-operative).
  8. Have normal corneal topography as determined by the Investigator.
  9. Anticipated postoperative stromal thickness of at least 350 microns.
  10. Have discontinued use of contact lenses for at least 2 weeks (for hard or toric lenses) or 3 days (for soft contact lenses) prior to the pre-operative examination, and through the day of surgery.
  11. All contact lens wearers must demonstrate a stable refraction (within ± 0.5 D), as determined by MRSE, on two consecutive examinations at least 1 week apart, in an eye to be treated and the axis of cylinder should not differ by more than 15 degrees from the baseline cycloplegic refraction.
  12. Agree to emmetropia correction for each treated eye
  13. Have the ability to lie flat without difficulty.
  14. Are willing and able to comply with the schedule for all post-surgery follow-up visits.

Exclusion criteria

Exclusion Criteria:

  1. Subjects for whom the combination of their baseline corneal thickness and the planned operative parameters for the LASIK procedure would result in treatment depth less than 250 microns from corneal endothelium.
  2. Acute or chronic disease or illness that would increase operative risk or confound the results of the study (e.g., dry eye, cataract, immuno-compromise, rheumatoid arthritis, atopic disease, acne rosacea, disease, endocrine disorders, lupus, systemic connective tissue disease, diabetes, or severe atopic disease).
  3. Ocular conditions that may predispose the subject to future complications, including but not limited to:

    • History or evidence of retinal vascular disease
    • History or evidence of active corneal disease or infection (e.g., recurrent corneal erosion syndrome, herpes simplex or herpes zoster keratitis) in either eye.
    • History of or evidence of glaucoma or glaucoma suspect (e.g., IOP > 21 mmHg).
  4. Eyes for which the baseline manifest subjective refraction exhibits a difference greater than 0.50 D in sphere power, or a difference greater than 0.50 D in cylinder power, or a difference in cylinder axis of more than 15 degrees compared to the baseline cycloplegic subjective refraction. For manifest cylinder of less than 0.50 D, the difference in cylinder axis will not be taken into consideration.
  5. Subjects for whom the pre-operative assessment of the cornea indicates that one or both eyes are not suitable candidates for treatment based upon the Investigator's medical judgment.
  6. Have evidence of retinal vascular disease.
  7. Have a history of or have active corneal disease or infection (e.g., recurrent corneal erosion syndrome, herpes simplex or herpes zoster keratitis, etc.) in either eye.
  8. Have a known sensitivity to any study medication.
  9. Have central corneal scars affecting visual acuity or unstable keratometry with irregular mires in an eye considered for eligibility.
  10. Presence of keratoconus, subclinical or forme fruste keratoconus, corneal dystrophy, unstable central keratometry readings with irregular mires, or other corneal irregularity (e.g., irregular astigmatism).
  11. Had previous intraocular or corneal surgery in an eye considered for eligibility that might confound the outcome of the study or increase the risk to the subject.
  12. Use chronic medications by any administration route that may increase risk to the subject or may confound the outcome of the study, including those known to affect wound healing (e.g., , antimetabolites, etc.).
  13. Are taking medications with LASIK such as isotretinoin (Accutane) or amiodarone hydrochloride (Cordarone).
  14. Are known to be pregnant, lactating, or who plan to become pregnant during the course of the study.
  15. Have known sensitivity to medications used for standard LASIK.
  16. Have the presence of systemic disease likely to affect wound healing, e.g., autoimmune disease, systemic connective tissue disease, diabetes, or severe atopic disease.
  17. Are participating in any other ophthalmic clinical trial within 30 days of screening or during this clinical trial.
  18. Have an ocular muscle disorder including a strabismus or nystagmus, or other disorder affecting fixation.
  19. Have a history of or evidence of glaucoma or are a glaucoma suspect.
  20. Eyes with mesopic pupil size > 7.0 mm.
  21. Have a Schirmer's pre-operative test without anesthesia \< 4 mm/5 minutes
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    TENEO 317 Model 2 (1.28 US) Excimer Laser

    Device: TENEO 317 Model 2 (1.28 US) Excimer Laser

Interventions

  • DeviceTENEO 317 Model 2 (1.28 US) Excimer Laser

    Surgery to Treat Myopia or Myopic Astigmatism with Sphere between 0.00D and -1.00D

06

What researchers measure

Primary outcomes

  1. The percentage of eyes that achieve predictability (attempted versus achieved) of MRSE within ± 0.50 D

    Time frame: Assessed for approximately 12 months

  2. The percentage of eyes that achieve predictability (attempted versus achieved) of MRSE within ± 1.00 D

    Time frame: Assessed for approximately 12 months

  3. The percentage of eyes that achieve a UDVA of 20/40 or better

    Time frame: Assessed for approximately 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Sep 2027, 17 months later.

Of 106 industry-sponsored interventional studies with no phase under Astigmatism, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 19. This study's planned 17 months is above that.

Counting every sponsor, half of 183 studies reached it within 12 months; a quarter within 4 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Jan 30, 2026
StartEst.
Apr 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07377474
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Apr 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jan 30, 2026

Study contacts

Dennis Carson
Contact
dennis.carson@bausch.com
4035025307
Rosangela Sonner
study director · Bausch & Lomb Incorporated

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion